The fund seeks to track the total return performance of the benchmark index before fees and expenses by investing in companies in the United States.
The sub-adviser’s investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
The fund employs a passive management or indexing approach that is designed to track the performance of the Index.
The Index is composed of approximately 30 pharmaceutical or biotechnology companies that have a high strategic focus on the development of drugs that harness the body’s own immune system to fight cancer (immunotherapy).
Next, the research team invests significantly in the component securities that make up the Index.
In addition, the research team employs a representative sampling strategy, which means that the fund will hold a portfolio of securities with generally the same risk and return characteristics of the Index.
Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.
The fund utilizes a replication strategy, meaning it generally will invest in all of the component securities of the Index.
Also, the fund generally may invest up to 20% of its net assets in securities or other investments not included in the Index.
To the extent the Index concentrates in the securities of a particular industry or group of related industries, the fund will concentrate its investments to approximately the same extent as the Index.
However, the fund is estimated to concentrate in Immunotherapy Companies.
The fund seeks to replicate the total return performance of the benchmark index, before fees and expenses, by investing in companies outside the United States.
The sub-adviser’s investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
As part of its strategy, the fund employs a passive management or indexing approach to track the performance of the Index.
Next, the research team invests significantly in the component securities and depositary receipts that make up the Index.
The Index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China’s pharmaceutical and biotech related industries.
The Index includes pharmaceutical companies, biotech companies, drug manufacturers, diagnostics companies, wholesalers or distributors of biopharma products, and biopharma service providers.
Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.
The fund seeks to replicate the composition of the benchmark index, holding each security in approximately the same proportion as its weighting in the Underlying Index.
In addition, the fund employs a representative sampling strategy, which means that the fund will hold a portfolio of securities with generally the same risk and return characteristics of the Index.
To the extent the Index concentrates in the securities of a particular industry or group of related industries, the fund will concentrate its investments to approximately the same extent as the Index.
